15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English Gilead (the drug make of tenofovir) start HBV Vaccin ...
查看: 1039|回复: 1
go

Gilead (the drug make of tenofovir) start HBV Vaccine [复制链接]

Rank: 5Rank: 5

现金
609 元 
精华
帖子
367 
注册时间
2011-9-27 
最后登录
2022-11-15 
1
发表于 2011-10-29 06:01 |只看该作者 |倒序浏览 |打印
1. Gilead 开始开发治疗乙肝疫苗
2. Gilead: Viread (tenofovir) 2011 第二季度销售额 $1.857亿

From: http://www.genengnews.com/gen-news-highlights/gilead-and-globeimmune-ally-to-develop-hbv-vaccine-for-use-in-combination-with-viread/81245863/

Gilead and GlobeImmune Ally to Develop HBV Vaccine for Use in Combination with Viread
Gilead and GlobeImmune Inked an exclusive worldwide license and collaboration agreement centered on the development of therapeutic vaccines for use in combination with Gilead’s marketed drug Viread® (tenofovir disoproxil fumarate) and other treatments for chronic hepatitis B virus (HBV) infection. Gilead will pay its partner an up-front payment and provide support for GlobeImmune’s continued development of its HBV therapeutic vaccine through Phase Ia clinical trials. Gilead will then be able to take over full responsibility for further development of the vaccine, in return for additional development milestones and royalties on future sales.
GlobeImmune is focused the development of therapeutic Tarmogen vaccines for the treatment of infectious diseases and cancer. Tarmogen vaccines are whole, heat-killed recombinant Saccharomyces cerevisiae yeast cells engineered to produce one or more target disease antigens, such as viral proteins or cancer-associated proteins. The company’s lead infectious disease product candidate, GI-5005, is a Tarmogen vaccine in Phase II development for the treatment of chronic hepatitis C infection (HCV).
The collaboration with Gilead aims to generate therapeutic vaccine products that have a specific HBV DNA antigens cloned into S. cerevisiae. The firms anticipate that combining a therapeutic vaccine with oral suppressive antiviral therapy will help increase surface antigen (HBsAg) loss with seroconversion. “Based on the proof-of-concept studies in hepatitis C infection, we believe that the combination of GlobeImmune’s Tarmogen immunotherapy products with oral suppressive antiviral therapy will help eliminate the cells harboring the hepatitis B virus, thus increasing seroconversion within a finite period,” remarks David Apelian, M.D., senior vp of R&D, and CMO at GlobeImmune.
Gilead reported sales of Viread for the treatment of HIV infection and chronic HBV were $185.7 million in the second quarter of 2011, up from $176.2 million in the second quarter of 2010.
已有 1 人评分现金 收起 理由
我随心动 + 10 thx

总评分: 现金 + 10   查看全部评分

Rank: 5Rank: 5

现金
4175 元 
精华
帖子
688 
注册时间
2006-1-22 
最后登录
2013-5-23 
2
发表于 2011-11-16 02:59 |只看该作者
本帖最后由 cshbv 于 2011-11-16 03:00 编辑

Based on poc for hep c, they believe it can help eliminate hepb... Am I missing something here?
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-6-16 05:46 , Processed in 0.014059 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.